HERG subunit composition determines differential drug sensitivity

British Journal of Pharmacology

Volumn 164, Issue 2 B, 2011, Pages 419-432

  Abi Gerges, N ^a   Holkham, H ^a   Jones, E M C ^b   Pollard, C E ^a   Valentin, J P ^a   Robertson, G A ^b  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

arrhythmia; drug sensitivity; hERG; hERG 1a; hERG 1b; hERG blockers; K v11.1; KCNH2; safety assessment; torsades de pointes

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; AJMALINE; ALFUZOSIN; ALMOKALANT; AMIODARONE; AMITRIPTYLINE; AMLODIPINE; ASTEMIZOLE; AZIMILIDE; BEPRIDIL; CETIRIZINE; CHLORPHENIRAMINE; CISAPRIDE; DESIPRAMINE; DILTIAZEM; DIPHENHYDRAMINE; DOFETILIDE; DOMPERIDONE; EBASTINE; ENCAINIDE; FLECAINIDE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL HERG 1A; POTASSIUM CHANNEL HERG 1B; SOTALOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN STABILITY;

ACTION POTENTIALS; ARRHYTHMIAS, CARDIAC; CELL LINE, TRANSFORMED; DRUG EVALUATION, PRECLINICAL; ETHER-A-GO-GO POTASSIUM CHANNELS; FLUOXETINE; HEK293 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LONG QT SYNDROME; PIPERIDINES; PROTEIN SUBUNITS; PYRIDINES; SENSITIVITY AND SPECIFICITY; TORSADES DE POINTES;

EID: 80052199035     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01378.x     Document Type: Article

References (43)

1. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, et al,. (1999). MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97: 175-187.
2. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br. J. Pharmacol 158 (Suppl. 1): S1-S254.
3. Bridgland-Taylor MH, Hargreaves AC, Easter A, Orme A, Henthorn DC, Ding M, et al,. (2006). Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWork™ HT. J Pharmacol Toxicol Methods 54: 189-199. (Pubitemid 44308866)
4. + channels. Circ Res 82: 386-395. (Pubitemid 28101196)
5. + channels. Mol Pharmacol 60: 1343-1348. (Pubitemid 33144905)
6. Guo L, Guthrie H, (2005). Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. J Pharmacol Toxicol Methods 52: 123-135. (Pubitemid 41008636)
7. Hancox JC, Micheson JS, (2006). Combined hERG channel inhibition and discruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology. Br J Pharmacol 149: 457-459. (Pubitemid 44658505)
8. Harmer AR, Abi-Gerges N, Easter A, Woods A, Lawrence CL, Small BG, et al,. (2008). Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWork™. J Pharmacol Toxicol Methods 57: 30-41. (Pubitemid 350137787)
9. Herzberg IM, Trudeau MC, Robertson GA, (1998). Transfer of rapid inactivation and E-4031 sensitivity from HERG to M-EAG Channels. J Physiol 511.1: 3-14. (Pubitemid 28421307)
10. Jones EM, Roti Roti EC, Wang J, Delfosse SA, Robertson GA, (2004). Cardiac IKr channels minimally comprise hERG 1a and 1b subunits. J Biol Chem 279: 44690-44694. (Pubitemid 39430878)
11. Kirsch GE, Trepakova ES, Brimecombe JC, Sidach SS, Erickson HD, Kochan MC, et al,. (2004). Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods 50: 93-101. (Pubitemid 39286321)
12. Kiss L, Bennett PB, Uebele VN, Koblan KS, Kane SA, Neagle B, et al,. (2003). High throughput ion channel pharmacology: planar-array-based voltage clamp. Assay Drug Dev Technol 1: 127-135.
13. Kupershmidt S, Yang IC, Hayashi K, Wei J, Chanthaphaychith S, Petersen CI, et al,. (2003). The IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines. FASEB J 17: 2263-2265. (Pubitemid 39561460)
14. Larsen AP, Olesen SP, Grunnet M, Jespersen T, (2008). Characterization of hERG1a and hERG1b potassium channels-a possible role for hERG1b in the I(Kr) current. Pflugers Arch 456: 1137-1148.
15. Larsen AP, Bentzen BH, Grunnet M, (2010). Differential effects of Kv11.1 activators on Kv11.1a, Kv11.1b and Kv11.1a/Kv11.1b channels. Br J Pharmacol 161: 614-628.
16. Lees-Miller JP, Kondo C, Wang L, Duff HJ, (1997). Electrophysiological characterization of an alternatively processed ERG K+ channel in mouse and human hearts. Circ Res 81: 719-726. (Pubitemid 27467207)
17. Lees-Miller JP, Duan Y, Teng GQ, Duff HJ, (2000). Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol Pharmacol 57: 367-374. (Pubitemid 30084514)
18. Lees-Miller JP, Guo J, Somers JR, Roach DE, Sheldon RS, Rancourt DE, et al,. (2003). Selective knockout of mouse ERG1 B potassium channel eliminates I(Kr) in adult ventricular myocytes and elicits episodes of abrupt sinus bradycardia. Mol Cell Biol 23: 1856-1862. (Pubitemid 36278800)
19. + current. Circ Res 81: 870-878. (Pubitemid 27467223)
20. Männikkö R, Overend G, Perrey C, Gavaghan CL, Valentin JP, Morten J, et al,. (2010). Pharmacological and electrophysiological characterization of nine, single nucleotide polymorphisms of the hERG-encoded potassium channel. Br J Pharmacol 159: 102-114.
21. McDonald TV, Yu Z, Ming Z, Palma E, Meyers MB, Wang KW, et al,. (1997). A minK-HERG complex regulates the cardiac potassium current I(Kr). Nature 388: 289-292. (Pubitemid 27317974)
22. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC, (2000a). A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 97: 12329-12333.
23. Mitcheson JS, Chen J, Sanguinetti MC, (2000b). Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J Gen Physiol 115: 229-240.
24. Pollard CE, Abi Gerges N, Bridgland-Taylor MH, Easter A, Hammond TG, Valentin JP, (2010). An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol 159: 12-21.
25. Rajamani S, Eckhardt LL, Valdivia CR, Klemens CA, Gillman BM, Anderson CL, et al,. (2006). Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 149: 481-489. (Pubitemid 44658508)
26. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al,. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 32-45. (Pubitemid 36351620)
27. Sale H, Wang J, O'Hara TJ, Tester DJ, Phartiyal P, He JQ, et al,. (2008). Physiological Properties of hERG 1a/1b Heteromeric Currents and a hERG 1b-Specific Mutation Associated With Long-QT Syndrome. Circ Res 103: e81-e95.
28. Sanguinetti MC, Jiang C, Curran ME, Keating MT, (1995). A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81: 299-307.
29. Schroeder K, Neagle B, Trezise DJ, Worley J, (2003). IonWorksTM HT: a new high-throughput electrophysiology measurement platform. J Biomol Screen 8: 50-64.
30. Schulz M, Schmoldt A, (2003). Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 58: 447-474. (Pubitemid 36869876)
31. Snyders DJ, Chaudhary A, (1996). High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol 49: 949-955. (Pubitemid 26181422)
32. Sorota S, Zhang XS, Margulis M, Tucker K, Priestley T, (2005). Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen. Assay Drug Dev Technol 3: 47-57. (Pubitemid 40533252)
33. + channel. Open-channel block by methanesulfonanilides. Circ Res 78: 499-503.
34. Subbiah RN, Clarke CE, Smith DJ, Zhao J, Campbell TJ, Vandenberg JI, (2004). Molecular basis of slow activation of the human ether-a-go-go related gene potassium channel. J Physiol 558: (Pt 2): 417-431. (Pubitemid 39117592)
35. Tao H, Ana DS, Guia A, Huang M, Ligutti J, Walker G, et al,. (2004). Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol 2: 497-506. (Pubitemid 39619092)
36. Thomas D, Gut B, Wendt-Nordahl G, Kiehn J, (2002). The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J Pharmacol Exp Ther 300: 543-548.
37. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA, (1995). HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269: 92-95.
38. Valentin JP, Hammond T, (2008). Safety and secondary pharmacology: successes, threats, challenges and opportunities. J Pharmacol Toxicol Methods 58: 77-87.
39. Valentin JP, Pollard CE, Lainée P, Hammond TG, (2010). Value of non-clinical cardiac repolarization assays in supporting the discovery and development of safer medicines. Br J Pharmacol 159: 25-33.
40. Wang S, Morales MJ, Liu S, Strauss HC, Rasmusson RL, (1997). Modulation of HERG affinity for E-4031 by [K+]o and C-type inactivation. FEBS Lett 417: 43-47. (Pubitemid 27490469)
41. Wang X, Li M, (2003). Automated electrophysiology: high throughput of art. Assay Drug Dev Technol 1: 695-708.
42. Wang X, Xu R, Abernathey G, Taylor J, Alzghoul MB, Hannon K, et al,. (2008). Kv11.1 channel subunit composition includes MinK and varies developmentally in mouse cardiac muscle. Dev Dyn 237: 2430-2437.
43. Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, et al,. (1998). Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J 74: 230-241. (Pubitemid 28041752)